JCEM: 巯 treatment with acute pancreatitis risk.

The European Medical Institution (EMA) recently issuedwarning of an increased risk of acute pancreatitis (AP) in MMI users.
a study published in Journal of Clinical Endocrinology and Metabolism, an authoritative journal in the field of endocrine and metabolic diseases, explores the link between MMI and AP in a population-based study.
researchers conducted a retrospective analysis of the administrative health database (2013-2018).
data from: i) Resident Registry, ii) Discharge Records (ICD-9-CM 577.0), iii) Drug Registry (ATC H03BB02).
researchers assessed the AP risk of MMI users over an 18-month period of treatment and layered the results.
researchers used Poisson regression to estimate age and gender-adjusted ratio (RR) and relatively 95% confidence interval (CI), and compared the AP rates of MMI users and non-users.
researchers also calculated the absolute risk of AP occurring in MMI users.
study identified a total of 23,087 new MMI users.
, 61 patients were hospitalized during the study period.
AP risk increased significantly during the first three quarters of treatment (RR was 3.40 (95% CI was 2.12-5.48), RR was 2.40 (95% CI was 1.36-4.23), and RR was 2.80 (95% CI 1.66-4.73) but disappeared thereafter.
the first 18 months of treatment, the absolute risk of AP was less than 0.4% for MMI users of all genders and ages.
the results of this study support EMA warnings, indicating an increased AP risk associated with MMI.
, however, this increase appears to be limited to the first few months of MMI treatment.
, in absolute terms, MMI users are less likely to have ANPs, well below 1%.
.